Evidence map›Paper›PMID 36700131›Full record

ArticleTherapeutic advances in medical oncology2023

Identification of a large intra-exonic deletion in

Inès Debbabi, Sophie Vacher, Cindy Neuzillet, Jérome Cros, Françoise Revillon, Ambre Petitalot, Anthony Turpin, Samantha Antonio, Elodie Girard, Célia Dupain and 5 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Inès DebbabiDepartment of Genetics, Institut Curie, Paris, France.
Sophie VacherDepartment of Genetics, Institut Curie, Paris, France.ORCID https://orcid.org/0000-0002-0042-6023
Cindy NeuzilletDepartment of Medical Oncology, Curie Institute, Versailles Saint Quentin University, Paris, France.
Jérome CrosINSERM UMR1149, Beaujon University Hospital, Paris University, Paris, France.
Françoise RevillonUnit of Human Molecular Oncology, Centre Oscar Lambret, Lille, France.
Ambre PetitalotDepartment of Genetics, Institut Curie, Paris, France.
Anthony TurpinULR9020-UMR-S 1277 Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France.ORCID https://orcid.org/0000-0002-2282-0101
Samantha AntonioDepartment of Genetics, Institut Curie, Paris, France.
Elodie GirardINSERM UMR1149, Institut Curie, Paris, France.
Célia DupainDepartment of Drug Development and Innovation, Institut Curie, PSL Research University, Paris.
Maud KamalDepartment of Drug Development and Innovation, Institut Curie, PSL Research University, Paris.
Pascal HammelDepartment of Digestive and Medical Oncology, Paris-Saclay University, Hôpital Paul Brousse, Villejuif, France.
Ivan BiècheDepartment of Genetics, Institut Curie, Paris, France.
Julien Masliah-PlanchonDepartment of Genetics, Institut Curie, Paris, France.
Sandrine M CaputoDepartment of Genetics, Institut Curie, Paris, France.ORCID https://orcid.org/0000-0001-5338-9388
Université Paris Sciences et Lettres · FRInserm · FRCentre National de la Recherche Scientifique · FRCentre Oscar Lambret · FRInstitut Curie · FRUniversité Paris Cité · FRUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

By 2030, pancreatic cancer will become the second leading cause of cancer-related deaths in the United States and in Europe. The management of patients with advanced pancreatic cancer relies on chemotherapy and poly (ADP-ribose) polymerase inhibitors for patients who carry

Indexed as

BRCA2deletionpancreatic cancerrearrangementvariant of unknown significance

Identifiers

PMID36700131
PMCPMC9869184
OpenAlexW4318169417

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.